PR Newswire Clinical TrialsOriginal article
Skyhawk Therapeutics publie les résultats à douze mois des sous-composantes de la cUHDRS issus de son essai clinique de phase 1/2 de SKY-0515 dans le traitement de la maladie de Huntington
Phase 1positiveSKY-0515Positive
AI Analysis
Summary
Skyhawk Therapeutics reported positive 12-month data from its Phase 1/2 trial of SKY-0515 in Huntington's disease, showing favorable trends across cUHDRS sub-components including functional capacity and motor scores.
Clinical Trial Data
Phase
1/2
Primary Endpoint
Met
Outcome Details
12-month data showed favorable and consistent trends across four cUHDRS sub-components including total functional capacity (TFC), total motor score (TMS), and symbol digit substitution test
Importance:6/10
Sentiment:
0.70
Huntington's diseaseClinical dataPhase 1/2SKY-0515neurodegeneration
Read the original article
Published by PR Newswire Clinical Trials on July 1, 2026 9:28 PM